D

Duality Biologics Tech Stack

Clinical-stage ADC biotech advancing 4 programs in global trials

Biotechnology Research Shanghai 201–500 employees Founded 2020 Privately Held

Duality Biologics is a Shanghai-based ADC (antibody-drug conjugate) company with 4 assets in clinical development and 10+ preclinical candidates. The tech stack—WinNonlin, Monolix, PyTorch, TensorFlow, R, Python, plus LangChain and LangGraph—reveals dual competencies: pharmacokinetic/pharmacodynamic modeling and emerging AI-driven workflows for research acceleration. Active hiring skews heavily research (6 roles) and leadership (7 director/VP/medical director positions), signaling both technical depth in chemistry/biology and scaling pressures on clinical execution.

Tech Stack 17 technologies

Core StackPython PyTorch TensorFlow Docker LangChain RAG SAP WinNonlin Monolix R Git LangGraph Transformer PowerPoint Excel NotebookLM Claude

What Duality Biologics Is Building

◆Challenges

Clinical trial risk management
Preclinical asset advancement
Biomarker development
Regulatory submissions
Accelerating drug discovery
Clinical data analysis complexity
Clinical development process inefficiencies
Clinical data analysis to decision-making
Accelerating fast growth
Clinical development planning

▲Active Projects

Tce platform development
Next-generation adc platform innovation
Pipeline progression to ind submission
Dose optimization
Drug-drug interaction (ddi)
Formulation bridging
Translational strategy for preclinical assets
Biomarker assay development
Data integration for biomarker data
Llm agent building

Hiring Activity

Steady15 roles · 5 in 30d

Department

Research

6

Healthcare

3

Data

1

Executive

1

Finance

1

Legal

1

Seniority

Director

4

Senior

4

VP

3

Manager

1

Mid

1

Notable leadership hires: Medical Director

Company intelligence

Find more companies like Duality Biologics by tech stack, pain points and active projects

Get started free

About Duality Biologics

Duality Biologics develops next-generation ADC therapeutics targeting oncology and autoimmune disease. The company operates from Shanghai and has established multiple proprietary ADC technology platforms with global IP coverage. The pipeline includes 4 programs in international multi-center clinical trials (MRCT) and 10+ preclinical programs. Near-term focus spans dose optimization, formulation bridging, biomarker assay development, and advancement of preclinical assets toward investigational new drug (IND) submissions. The company has signed licensing partnerships with multinational pharma partners globally.

HeadquartersShanghai

Company Size201–500 employees

Founded2020

Hiring MarketsChina

Frequently Asked Questions

What is Duality Biologics working on?

Duality develops ADC therapies for cancer and autoimmune diseases. Current work includes TCE platform development, next-generation ADC platform innovation, pipeline progression to IND submission, dose optimization, drug-drug interaction studies, and biomarker assay development.

What tech stack does Duality Biologics use?

Research and development tools: WinNonlin, Monolix, R, Python, PyTorch, TensorFlow. Infrastructure: Git, Docker. AI/ML: LangChain, LangGraph, RAG, Transformer, Claude. Enterprise: SAP, PowerPoint, Excel, NotebookLM.